XKRX
063160
Market cap57mUSD
Oct 08, Last price
14,010.00KRW
1D
-7.03%
1Q
4.71%
Jan 2017
-37.54%
IPO
294.09%
Name
CKD Bio Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, including fermentation, chemical synthesis, and biotechnology. The company's extensive portfolio of APIs targets a broad spectrum of therapeutic applications, encompassing antibiotics, beta-lactamase inhibitors, immunosuppressants, oncology treatments, anti-obesity medications, dry eye remedies, antiviral and antituberculosis agents, antihyperlipidemics, and probiotics. Beyond its core manufacturing, CKD Bio Corp. also provides contract research, development, and manufacturing (CRDMO) services for APIs, pharmaceutical intermediates, and probiotic formulations. The company actively exports its products, establishing a global reach.
Key people
Hak Yeon Hwang
Assistant Managing Director
Hae Mun Lee
Internal Auditor
Joeng Jin Lee
Chief Executive Officer, Director · since 2017
Assistant Managing Director · since 2012
Gwang Seop Gil
Non-Executive Independent Director · since 2008
Headquarters & legal address
서울특별시 서대문구 충정로 8
5층
Seoul, 11 03742
KR
5층
Seoul, 11 03742
KR
Address
8, Chungjeong-ro, Seodaemun-gu, Seoul
5F
Seoul, 11 03742
KR
5F
Seoul, 11 03742
KR
Other language
CKD Bio Corporation
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||